Figure 1.
Mild functional defects of VWF are common in patients with low VWF. (A) VWF:Act and VWF:Ag levels in the total low VWF cohort (n = 214) at the time of diagnosis. The blue area indicates patients with plasma VWF:Ag in the 30 to 50 IU/dL range (ie, low VWF–QT). The red area indicates patients with isolated VWF:Act in the 30 to 50 IU/dL range and plasma VWF:Ag levels of >50 IU/dL (ie, low VWF–QL). (B) In 103 of the 214 (48.1%) in our total cohort, a low VWF diagnosis was based on an isolated VWF:Act in the 30 to 50 IU/dL range, whereas VWF:Ag was above 50 IU/dL (low VWF–QL). The remaining 111 patients (51.9%) had VWF:Ag levels in the 30 to 50 IU/dL range (low VWF–QT). (C) Diagram illustrating the number and types of VWF assays that showed reduced levels in patients with low VWF–QL. (D) The plasma VWF:Act/VWF:Ag ratio at diagnosis and at enrolment into the study (with mean time interval of 8.2 years) for patients with low VWF–QL (red) and those with low VWF–QT (blue).

Mild functional defects of VWF are common in patients with low VWF. (A) VWF:Act and VWF:Ag levels in the total low VWF cohort (n = 214) at the time of diagnosis. The blue area indicates patients with plasma VWF:Ag in the 30 to 50 IU/dL range (ie, low VWF–QT). The red area indicates patients with isolated VWF:Act in the 30 to 50 IU/dL range and plasma VWF:Ag levels of >50 IU/dL (ie, low VWF–QL). (B) In 103 of the 214 (48.1%) in our total cohort, a low VWF diagnosis was based on an isolated VWF:Act in the 30 to 50 IU/dL range, whereas VWF:Ag was above 50 IU/dL (low VWF–QL). The remaining 111 patients (51.9%) had VWF:Ag levels in the 30 to 50 IU/dL range (low VWF–QT). (C) Diagram illustrating the number and types of VWF assays that showed reduced levels in patients with low VWF–QL. (D) The plasma VWF:Act/VWF:Ag ratio at diagnosis and at enrolment into the study (with mean time interval of 8.2 years) for patients with low VWF–QL (red) and those with low VWF–QT (blue).

or Create an Account

Close Modal
Close Modal